EFFECTOR THERAPUTCS INC (EFTR)
EFTR moved a median of +0.47% 30 minutes after news, and 0.00% by the close. How EFTR actually reacts to news — the realized, point-in-time move the market made, measured across 95 labeled events over the last three years with zero look-ahead.
EFTR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.19% | 53% | 88 |
| 30-min | +0.47% | 51% | 95 |
| 60-min | 0.00% | 46% | 95 |
| to close | 0.00% | 46% | 95 |
| Middle 50% of EFTR reactions | -0.47% to +2.14% |
|---|---|
| Median reaction (30-min) | +0.47% |
| Measured reactions | 95 |
Half of all EFFECTOR THERAPUTCS INC news events land between -0.47% and +2.14% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when EFTR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EFTR's baseline. Nothing else.
Recent EFTR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form EFFECT eFFECTOR Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +1.21% | |
| Form 15-12G eFFECTOR Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | +0.00% | +0.00% | |
| Form POS AM eFFECTOR Therapeutics, | SEC filing · Form POS | SEC EDGAR | +0.00% | +0.00% | |
| Form S-8 POS eFFECTOR Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K eFFECTOR Therapeutics, For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | -11.80% | |
| Form 8-K eFFECTOR Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | -11.80% | |
| eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq | Press release | GlobeNewswire | +10.62% | -3.08% | |
| Form 8-K eFFECTOR Therapeutics, For: Jun 21 | SEC filing · Form 8-K | SEC EDGAR | +10.62% | -3.08% | |
| Form 8-K eFFECTOR Therapeutics, For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | -0.80% | |
| eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer | Press release | GlobeNewswire | +1.55% | -3.11% | |
| Form 8-K eFFECTOR Therapeutics, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +1.55% | -3.11% | |
| Form 8-K eFFECTOR Therapeutics, For: May 16 | SEC filing · Form 8-K | SEC EDGAR | +1.55% | -3.11% | |
| eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.19% | -2.87% | |
| Form 10-Q eFFECTOR Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.19% | -2.87% | |
| Form 8-K eFFECTOR Therapeutics, For: May 09 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | -2.87% | |
| Form 8-K/A eFFECTOR Therapeutics, For: May 09 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | -2.87% | |
| Form ARS eFFECTOR Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.65% | +4.42% | |
| Form DEF 14A eFFECTOR Therapeutics, For: Jun 13 | SEC filing · Form DEF | SEC EDGAR | +1.65% | +4.42% | |
| Form DEFA14A eFFECTOR Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.65% | +4.42% | |
| Form PRE 14A eFFECTOR Therapeutics, For: Jun 13 | SEC filing · Form PRE | SEC EDGAR | +1.44% | +5.29% | |
| eFFECTOR Therapeutics to Participate in Upcoming Investor Conference | Press release | GlobeNewswire | -0.46% | +6.45% | |
| eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer | Press release | GlobeNewswire | -6.11% | -17.78% | |
| Form 8-K eFFECTOR Therapeutics, For: Apr 04 | SEC filing · Form 8-K | SEC EDGAR | -6.11% | -17.78% | |
| Form EFFECT eFFECTOR Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -1.25% | +7.93% | |
| Form POS AM eFFECTOR Therapeutics, | SEC filing · Form POS | SEC EDGAR | -0.69% | +9.05% | |
| Form S-8 eFFECTOR Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.69% | +9.05% | |
| Form 10-K eFFECTOR Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.87% | +5.04% | |
| eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.87% | +5.04% | |
| Form 8-K eFFECTOR Therapeutics, For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +1.87% | +5.04% | |
| eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +1.22% | -4.80% | |
| Form 8-K eFFECTOR Therapeutics, For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +3.94% | -1.05% | |
| eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | +3.94% | -1.05% | |
| Form 8-K eFFECTOR Therapeutics, For: Jan 24 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +12.18% | |
| eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | +2.91% | +2.02% | |
| Thinking about buying stock in LAVA Therapeutics, UP Fintech Holding, Babcock & Wilcox Enterprises, Safety Shot, or eFFECTOR Therapeutics? | Press release | PR Newswire | +2.15% | +1.91% | |
| Form 8-K eFFECTOR Therapeutics, For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -1.51% | -2.63% | |
| eFFECTOR Therapeutics Announces Reverse Stock Split | Press release | GlobeNewswire | +6.17% | +8.01% | |
| eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024 | Press release | GlobeNewswire | +6.17% | +8.01% | |
| Form 8-K eFFECTOR Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -1.80% | +1.32% | |
| eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients | Press release | GlobeNewswire | -3.68% | -10.70% | |
| Form 8-K eFFECTOR Therapeutics, For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | -3.68% | -10.70% | |
| eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer | Press release | GlobeNewswire | -3.69% | -8.51% | |
| Form 8-K eFFECTOR Therapeutics, For: Nov 28 | SEC filing · Form 8-K | SEC EDGAR | -3.69% | -8.51% | |
| eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting | Press release | GlobeNewswire | -0.70% | +2.63% | |
| eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.57% | +0.73% | |
| Form 10-Q eFFECTOR Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.57% | +0.73% | |
| Form 8-K eFFECTOR Therapeutics, For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +3.57% | +0.73% | |
| eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference | Press release | GlobeNewswire | -0.46% | +3.24% | |
| eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia | Press release | GlobeNewswire | +1.61% | +1.79% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EFTR section they belong to.
Where else EFTR is measured.
EFTR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is EFFECTOR THERAPUTCS INC's median reaction calculated?
Every labeled EFTR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 95 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of EFTR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EFTR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.